Skip to main content

Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.

Publication ,  Journal Article
DeFilipp, Z; Peled, JU; Li, S; Mahabamunuge, J; Dagher, Z; Slingerland, AE; Del Rio, C; Valles, B; Kempner, ME; Smith, M; Brown, J; Dey, BR ...
Published in: Blood Adv
April 10, 2018

We hypothesized that third-party fecal microbiota transplantation (FMT) may restore intestinal microbiome diversity after allogeneic hematopoietic cell transplantation (allo-HCT). In this open-label single-group pilot study, 18 subjects were enrolled before allo-HCT and planned to receive third-party FMT capsules. FMT capsules were administered no later than 4 weeks after neutrophil engraftment, and antibiotics were not allowed within 48 hours before FMT. Five patients did not receive FMT because of the development of early acute gastrointestinal (GI) graft-versus-host disease (GVHD) before FMT (n = 3), persistent HCT-associated GI toxicity (n = 1), or patient decision (n = 1). Thirteen patients received FMT at a median of 27 days (range, 19-45 days) after HCT. Participants were able to swallow and tolerate all FMT capsules, meeting the primary study endpoint of feasibility. FMT was tolerated well, with 1 treatment-related significant adverse event (abdominal pain). Two patients subsequently developed acute GI GVHD, with 1 patient also having concurrent bacteremia. No additional cases of bacteremia occurred. Median follow-up for survivors is 15 months (range, 13-20 months). The Kaplan-Meier estimates for 12-month overall survival and progression-free survival after FMT were 85% (95% confidence interval, 51%-96%) and 85% (95% confidence interval, 51%-96%), respectively. There was 1 nonrelapse death resulting from acute GI GVHD (12-month nonrelapse mortality, 8%; 95% confidence interval, 0%-30%). Analysis of stool composition and urine 3-indoxyl sulfate concentration indicated improvement in intestinal microbiome diversity after FMT that was associated with expansion of stool-donor taxa. These results indicate that empiric third-party FMT after allo-HCT appears to be feasible, safe, and associated with expansion of recipient microbiome diversity. This trial was registered at www.clinicaltrials.gov as #NCT02733744.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

April 10, 2018

Volume

2

Issue

7

Start / End Page

745 / 753

Location

United States

Related Subject Headings

  • Survival Analysis
  • Pilot Projects
  • Middle Aged
  • Microbiota
  • Male
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Graft vs Host Disease
  • Gastrointestinal Tract
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DeFilipp, Z., Peled, J. U., Li, S., Mahabamunuge, J., Dagher, Z., Slingerland, A. E., … Chen, Y.-B. (2018). Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv, 2(7), 745–753. https://doi.org/10.1182/bloodadvances.2018017731
DeFilipp, Zachariah, Jonathan U. Peled, Shuli Li, Jasmin Mahabamunuge, Zeina Dagher, Ann E. Slingerland, Candice Del Rio, et al. “Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.Blood Adv 2, no. 7 (April 10, 2018): 745–53. https://doi.org/10.1182/bloodadvances.2018017731.
DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2018 Apr 10;2(7):745–53.
DeFilipp, Zachariah, et al. “Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.Blood Adv, vol. 2, no. 7, Apr. 2018, pp. 745–53. Pubmed, doi:10.1182/bloodadvances.2018017731.
DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, van den Brink MRM, Hohmann E, Jenq RR, Chen Y-B. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2018 Apr 10;2(7):745–753.

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

April 10, 2018

Volume

2

Issue

7

Start / End Page

745 / 753

Location

United States

Related Subject Headings

  • Survival Analysis
  • Pilot Projects
  • Middle Aged
  • Microbiota
  • Male
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Graft vs Host Disease
  • Gastrointestinal Tract
  • Female